Stock Movers Novo Nordisk Up, Legrand Plunges, Zalando Rises
Nov 6, 2025
Chloe Millay, a Bloomberg reporter specializing in market analysis, dives into the financial landscape. She discusses Novo Nordisk's stock rally following a judge's ruling favoring their $10 billion bid for Metsera. Legrand's third-quarter sales fall short of expectations, reflecting a slowdown in data-center demand, which could impact competitors. In contrast, Zalando shines with a third-quarter sales beat and a €100 million share buyback, boosting investor confidence. Insights into these market movements illustrate a dynamic trading environment.
AI Snips
Chapters
Transcript
Episode notes
MetSera Bid Clears Legal Hurdle
- A judge denied Pfizer's bid to block Novo Nordisk's $10bn offer for MetSera, clearing the way for an escalating bidding war.
- The failed block and a pending U.S. pricing deal with Eli Lilly likely helped erase recent share losses for Novo Nordisk.
U.S. Pricing Deal Softens Downbeat Forecasts
- CBS News reported the Trump administration plans a weight-loss drug pricing deal with Eli Lilly and Novo Nordisk that day, which markets viewed positively.
- Combined deal and bid news helped offset Novo Nordisk's earlier profit-forecast cuts.
Data-Center Slowdown Hits Legrand
- Legrand missed 3Q sales as demand for data-center infrastructure slowed after driving recent growth.
- The company's unchanged guidance signals likely weaker sales growth ahead and is a reality check for the sector.